Resultados del uso en cáncer de próstata del bloqueo androgénico completo en área de salud del Hospital de Referencia Tipo 2 (2ª Parte). Calidad de Vida: Aplicación del instrumento EORTC QLQ-PR25 y resultados globales. Supervivencia ajustada a la calidad de vida, gasto farmacéutico y coste-utilidad / Outcomes of maximal androgen blockade in prostate cancer patients at a health area with Type 2 Reference Hospital (2nd part). Quality of life: application of EORTC QLQ-PR25 instrument and global results. Quality-of-life adjusted survival. Pharmaceutical expenses and cost-utility
Arch. esp. urol. (Ed. impr.)
; 62(7): 571-572, sept. 2009.
Article
in Spanish
| IBECS
| ID: ibc-75903
Responsible library:
ES1.1
Localization: BNCS
Subject(s)
Full text:
Available
Collection:
National databases
/
Spain
Health context:
Sustainable Health Agenda for the Americas
Health problem:
Goal 4: Health financing
Database:
IBECS
Main subject:
Prostatic Neoplasms
/
Quality of Life
/
16672
/
Hormone Replacement Therapy
/
Hormones
/
Androgen Antagonists
/
Androgens
Type of study:
Health economic evaluation
Aspects:
Patient-preference
Limits:
Humans
/
Male
Language:
Spanish
Journal:
Arch. esp. urol. (Ed. impr.)
Year:
2009
Document type:
Article
Institution/Affiliation country:
Hospital del Mar/España
